Pozen (Nasdaq: POZN) hasn’t gotten any pain relief from the FDA recently – but it has from the U.S. Patent and Trademark Office.

The Chapel Hill-based drug firm said Tuesday that it had received a second patent for its technology that enables the combination of aspirin and so-called proton pump inhibitors. The latest one focuses on aspirin-based products.

Pozen believes PA product platform will lead to pain relievers that avoid the side effects aspiring can induce.

Under development are two combinations, PA32540 and PA8140.

Pozen is seeking commercial partners for the drugs.

The FDA last week said it wanted more tests on PA32540.